We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
9
Research Clients
260
Reports published
10k+
Readers in database
Congratulations to @MaxCyte_info on its @Nasdaq debut!
Strong FY21 trading emphasises resilience of #AllergyTherapeutics commercial business. Upcoming pipeline news has potential to transform medium-term prospects. Data expected from #PeanutAllergy biomarker study in Q3 & #GrassAllergy field trial in H2. $AGY https://www.trinitydelta.org/companies/allergy-therapeutics/
Two new Update notes on @hutchmed reinstating our valuation post IPO on @HKEXGroup & global offer, as well as covering key #ASCO21 takeaways for lead assets #surufatinib #savolitinib #fruquintinib & potential PD-1 combos.
For more on $HCM see: https://www.trinitydelta.org/companies/hutchmed/
We've reached a milestone - our 250th published report!
Visit our website for in-depth #healthcare & #lifesciences coverage on:
#AllergyTherapeutics @Parsortix @avacta #FuturaMedical @hutchmed @MaxCyte_info @NexstimOyj @RedxPharma @scancellpharma
https://www.trinitydelta.org/company-pages/
Two proprietary platforms (#Affimer & #PreCISION) with multiple applications provide @avacta with several attractive opportunities in #diagnostics &, longer-term, in #therapeutics.
Read our $AVCT.L initiation, So much more than a play on #COVIDtesting: https://www.trinitydelta.org/companies/avacta/
Leading CTC #liquidbiopsy player #ANGLEplc has raised £20m to support current initiatives in #mBC & #OvarianCancer, new opportunities to expand @Parsortix's utility (assessing #prostatecancer risk), & commercial expansion commercially. See our $AGL Update: https://www.trinitydelta.org/companies/angle/
Please sign up here to be added to our distribution database
';